BackgroundCheck.run
Search For

Richard J Caimi Deceased817 Shadywood Dr, Perkasie, PA 18944

Known as:
Rick J Caimi Dick J Caimi Jr Rick Caimi Richard John I
Related to:
Keeley J Caimi 27 Terica P Dickson 61 Aimee L Bross 46 William Wood 35 Thomas Dyer Cheryl Mangum 41

Richard Caimi Phones & Addresses

817 Shadywood Dr, Perkasie, PA 18944    215-2570494   

North Cape May, NJ   

Austin, TX   

Sellersville, PA   

1811 Norristown Rd, Ambler, PA 19002    215-6530467   

Ithaca, NY   

Montgomery, PA   

1811 Norristown Rd, Maple Glen, PA 19002   

Social networks

Richard J Caimi

Linkedin

Work

Company: Gsk Nov 2016 Position: Vice president: biopharm cmc development

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Cornell University 1991 to 1995 Specialities: Biochemistry

Skills

Biopharmaceuticals • Biotechnology • Gmp • Technology Transfer • Cell Culture • Validation • Analytical Chemistry • Fda • Drug Development • Purification • Life Sciences • Pharmaceutical Industry • Biochemistry • Clinical Development • Drug Discovery • Protein Chemistry • Pharmacology • Mass Spectrometry • Formulation • Sop • U.s. Food and Drug Administration • Standard Operating Procedure • Commercialization • Cmc Development

Industries

Biotechnology
Get Report
Control this profile

Mentions for Richard J Caimi

Richard Caimi resumes & CV records

Resumes

Richard Caimi Photo 10

Vice President: Biopharm Cmc Development

Location:
1811 Norristown Rd, Ambler, PA 19002
Industry:
Biotechnology
Work:
Gsk
Vice President: Biopharm Cmc Development Glaxosmithkline Pharma Gmbh Jan 2015 - Oct 2016
Head Biopharmaceutical External Development and Supply Gsk Jan 2014 - Dec 2014
Ceos Future Strategy Group Gsk Feb 2010 - Dec 2013
Director Early Phase Biopharm Cmc Development Promedior, Inc. Aug 2007 - Jan 2010
Director Analytical and Formulation Development Gsk 2000 - Aug 2007
Manager Biopharm Analytical Development Tvg 1997 - 1997
Senior Project Director Premier Amercican Technologies 1995 - 1996
Senior Scientist
Education:
Cornell University 1991 - 1995
Doctorates, Doctor of Philosophy, Biochemistry
Skills:
Biopharmaceuticals, Biotechnology, Gmp, Technology Transfer, Cell Culture, Validation, Analytical Chemistry, Fda, Drug Development, Purification, Life Sciences, Pharmaceutical Industry, Biochemistry, Clinical Development, Drug Discovery, Protein Chemistry, Pharmacology, Mass Spectrometry, Formulation, Sop, U.s. Food and Drug Administration, Standard Operating Procedure, Commercialization, Cmc Development

Publications & IP owners

Us Patents

Serum Amyloid P Derivatives And Their Preparation And Use

US Patent:
2010031, Dec 16, 2010
Filed:
Jun 4, 2010
Appl. No.:
12/794132
Inventors:
W. Scott Willett - Doylestown PA, US
Richard J. Caimi - Maple Glen PA, US
International Classification:
A61K 38/14
C07K 9/00
C12P 21/00
C12N 5/10
A61P 37/00
US Classification:
514 209, 530322, 435 691, 435 681, 435358
Abstract:
One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Pulmonary And Nasal Delivery Of Serum Amyloid P

US Patent:
2013006, Mar 14, 2013
Filed:
Sep 7, 2012
Appl. No.:
13/607240
Inventors:
W. Scott Willett - Doylestown PA, US
Richard J. Caimi - Maple Glen PA, US
Lynne Anne Murray - King of Prussia PA, US
Assignee:
Promedior, Inc. - Malvern PA
International Classification:
A61K 38/17
A61M 15/00
A61P 11/00
C07K 14/435
A61K 9/14
US Classification:
424400, 514 212, 530380, 12820312, 12820315
Abstract:
The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

Pulmonary And Nasal Delivery Of Serum Amyloid P

US Patent:
2010026, Oct 21, 2010
Filed:
Apr 1, 2010
Appl. No.:
12/752627
Inventors:
W. Scott Willett - Doylestown PA, US
Richard J. Caimi - Maple Glen PA, US
Lynne Anne Murray - King of Prussia PA, US
International Classification:
A61K 38/16
A61K 9/14
A61P 11/00
US Classification:
424400, 514 11
Abstract:
The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

Serum Amyloid P Derivatives And Their Preparation And Use

US Patent:
2023005, Feb 23, 2023
Filed:
Mar 15, 2022
Appl. No.:
17/695071
Inventors:
- Lexington MA, US
Richard J. Caimi - Maple Glen PA, US
International Classification:
C07K 14/47
Abstract:
One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Serum Amyloid P Derivatives And Their Preparation And Use

US Patent:
2020036, Nov 26, 2020
Filed:
Dec 31, 2019
Appl. No.:
16/731320
Inventors:
- Lexington MA, US
Richard J. Caimi - Maple Glen PA, US
International Classification:
C07K 14/47
Abstract:
One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Serum Amyloid P Derivatives And Their Preparation And Use

US Patent:
2018004, Feb 15, 2018
Filed:
Apr 20, 2017
Appl. No.:
15/492085
Inventors:
- Lexington MA, US
Richard J. Caimi - Maple Glen PA, US
International Classification:
C07K 14/47
Abstract:
One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Possible Relatives

Anthony Caimi  Brian D Caimi  Richard O Johnson  Richard E Stamps  Richard E Stanbrough  Richard H Stanchfield  Richard W Stanczyk  Richard M Standage  Richard A Standen  Richard F Standifer 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.